2018 Leibovich Model for Renal Cell Carcinoma (RCC)

ورودی‌های بالینی بیمار

حداقل ۱۸ — حداکثر ۱۰۰ • واحد: years

حداقل ۰.۵ — حداکثر ۲۵ • واحد: cm

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
leibovich score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Low Risk0–4
  • Intermediate Risk5–9
  • High Risk10–14
  • Very High Risk15–20
Direct Clinical Answer

The 2018 Leibovich Model for Renal Cell Carcinoma (RCC) calculator is designed for bedside predicting progression-free and cancer-specific survival in patients with renal cell carcinoma (RCC) using clinical, surgical, and pathologic factors in clinical practice. The resulting score directly guides clinician decision-making regarding adjusting systemic.

Clinical Guidelines & Evidence

Predicts progression-free and cancer-specific survival in patients with renal cell carcinoma (RCC) using clinical, surgical, and pathologic factors

Clinical Indication

The 2018 Leibovich Model for Renal Cell Carcinoma (RCC) is indicated for bedside clinical practice to support Predicts progression-free and cancer-specific survival in patients with renal cell carcinoma (RCC) using clinical, surgical, and pathologic factors. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.

Limitations & Contraindications

Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.

Clinical Pearls & Action Plan

Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival.

Formula & Variables:

Scoring based on clinical, surgical, and pathologic factors with separate models for progression-free survival (PFS) and cancer-specific survival (CSS)

Input Parameters

NameTypeRequiredDescription
ageintegerYesPatient's age at surgery in years(years)
ecog_statusstringYesECOG Performance Status
constitutional_symptomsbooleanYesPresence of constitutional symptoms (fever, night sweats, weight loss)
adrenalectomybooleanYesAdrenalectomy performed during surgery
surgical_marginsstringYesSurgical margin status
tumor_gradestringYesTumor grade (Fuhrman/WHO-ISUP grading)
coagulative_necrosisbooleanYesPresence of coagulative tumor necrosis
sarcomatoid_differentiationbooleanYesPresence of sarcomatoid differentiation
tumor_sizefloatYesMaximum tumor diameter in centimeters(cm)
perinephric_invasionbooleanYesInvasion of perinephric fat or renal sinus fat
tumor_thrombusstringYesPresence and level of tumor thrombus
extension_beyond_kidneybooleanYesExtension beyond kidney capsule

Score Interpretation & Guidance

RangeStageDescription
0–4Low RiskExcellent prognosis
5–9Intermediate RiskGood prognosis
10–14High RiskPoor prognosis
15–20Very High RiskVery poor prognosis

Evidence-Based References (EBM)

  • Thompson RH, Leibovich BC, Cheville JC, et al. Negative impact of sarcomatoid differentiation on the outcome of clear cell renal cell carcinoma. Am J Surg Pathol. 2018;42(4):474-481.
  • Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003;97(7):1663-71.
  • Thompson RH, Cheville JC, Lohse CM, et al. Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy. Cancer. 2005;104(1):53-60.

Related calculators